Please ensure Javascript is enabled for purposes of website accessibility

Why Zymeworks Stock Is Crashing Today

By Keith Speights - Jan 28, 2021 at 11:44AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company announced early data for an experimental cancer drug that disappointed investors.

What happened

Shares of Zymeworks (ZYME 7.85%) are crashing today, down by 23.7% as of 11:20 a.m. EST, after the company announced data late on Wednesday from the dose-escalation portion of a phase 1 study evaluating antibody-drug conjugate ZW49 in treating several types of HER2‑positive cancer.

So what

Zymeworks stated that there were "multiple confirmed responses and stable disease observed in several tumor types" in patients treated with ZW49. The company also said that the safety profile for the experimental therapy looked pretty good. While there were some adverse events, 90% of them were mild or moderate in severity.

Scientist looking through a microscope with another scientist in the background

Image source: Getty Images.

So why the big sell-off of the biotech stock today? Zymeworks' data was disappointing. As SVB Leerink analyst Andrew Berens wrote to clients, "The results fell well short of investor expectations for a 40%-50% response rate." 

Unsurprisingly, Zymeworks executives had a more optimistic take. Chief Medical Officer Diana Hausman said, "We are encouraged by the antitumor activity we are seeing so far with ZW49." CEO Ali Tehrani stated, "I believe ZW49 is on track for becoming the HER2 ADC that delivers efficacy without compromising safety."

At least one analyst also remained cautiously optimistic. Raymond James' David Novak acknowledged that Zymeworks' data fell short of expectations. However, he referred to the safety and tolerability profile of ZW49 as "class-leading" and said that it "creates opportunity" for the experimental drug.

Now what

The phase 1 dose-escalation study of ZW49 will continue. Zymeworks hasn't yet established the maximum tolerated dose for the therapeutic candidate. The biotech has also begun enrolling patients into the expansion cohort part of the ongoing study.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Zymeworks Inc. Stock Quote
Zymeworks Inc.
ZYME
$6.87 (7.85%) $0.50

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
344%
 
S&P 500 Returns
120%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.